QQQ   301.91 (-0.72%)
AAPL   119.24 (-0.74%)
MSFT   227.96 (+0.54%)
FB   259.61 (+0.76%)
GOOGL   2,060.09 (+1.29%)
TSLA   591.09 (-4.88%)
AMZN   2,960.89 (-0.56%)
NVDA   485.01 (-1.98%)
BABA   232.68 (+0.95%)
CGC   29.95 (-3.42%)
GE   13.58 (+0.07%)
MU   84.76 (+0.51%)
NIO   36.34 (-7.48%)
AMD   76.86 (-1.14%)
T   29.57 (+2.25%)
F   12.12 (+1.59%)
ACB   9.39 (-4.38%)
DIS   187.00 (-0.55%)
BA   223.29 (-0.63%)
NFLX   503.62 (-1.50%)
BAC   36.95 (+1.23%)
QQQ   301.91 (-0.72%)
AAPL   119.24 (-0.74%)
MSFT   227.96 (+0.54%)
FB   259.61 (+0.76%)
GOOGL   2,060.09 (+1.29%)
TSLA   591.09 (-4.88%)
AMZN   2,960.89 (-0.56%)
NVDA   485.01 (-1.98%)
BABA   232.68 (+0.95%)
CGC   29.95 (-3.42%)
GE   13.58 (+0.07%)
MU   84.76 (+0.51%)
NIO   36.34 (-7.48%)
AMD   76.86 (-1.14%)
T   29.57 (+2.25%)
F   12.12 (+1.59%)
ACB   9.39 (-4.38%)
DIS   187.00 (-0.55%)
BA   223.29 (-0.63%)
NFLX   503.62 (-1.50%)
BAC   36.95 (+1.23%)
QQQ   301.91 (-0.72%)
AAPL   119.24 (-0.74%)
MSFT   227.96 (+0.54%)
FB   259.61 (+0.76%)
GOOGL   2,060.09 (+1.29%)
TSLA   591.09 (-4.88%)
AMZN   2,960.89 (-0.56%)
NVDA   485.01 (-1.98%)
BABA   232.68 (+0.95%)
CGC   29.95 (-3.42%)
GE   13.58 (+0.07%)
MU   84.76 (+0.51%)
NIO   36.34 (-7.48%)
AMD   76.86 (-1.14%)
T   29.57 (+2.25%)
F   12.12 (+1.59%)
ACB   9.39 (-4.38%)
DIS   187.00 (-0.55%)
BA   223.29 (-0.63%)
NFLX   503.62 (-1.50%)
BAC   36.95 (+1.23%)
QQQ   301.91 (-0.72%)
AAPL   119.24 (-0.74%)
MSFT   227.96 (+0.54%)
FB   259.61 (+0.76%)
GOOGL   2,060.09 (+1.29%)
TSLA   591.09 (-4.88%)
AMZN   2,960.89 (-0.56%)
NVDA   485.01 (-1.98%)
BABA   232.68 (+0.95%)
CGC   29.95 (-3.42%)
GE   13.58 (+0.07%)
MU   84.76 (+0.51%)
NIO   36.34 (-7.48%)
AMD   76.86 (-1.14%)
T   29.57 (+2.25%)
F   12.12 (+1.59%)
ACB   9.39 (-4.38%)
DIS   187.00 (-0.55%)
BA   223.29 (-0.63%)
NFLX   503.62 (-1.50%)
BAC   36.95 (+1.23%)
Log in
OTCMKTS:AGNPF

Algernon Pharmaceuticals Stock Forecast, Price & News

$0.22
-0.03 (-12.02 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.22
Now: $0.22▼
$0.25
50-Day Range
$0.18
MA: $0.24▼
$0.30
52-Week Range
$0.06
Now: $0.22▼
$0.49
Volume893,625 shs
Average Volume982,313 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Algernon Pharmaceuticals Inc., a clinical stage pharmaceutical development company, focuses in the areas of nonÂ-alcoholic steatohepatitis, liver disease, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury. The company's lead candidate is NP-120, a N-methyl-D-aspartate (NMDA) receptor antagonist, which targets NMDA-type subunit 2B (Glu2NB) and prevents glutamate signalling. Algernon Pharmaceuticals Inc. is headquartered in Vancouver, Canada.

Headlines

Algernon Pharmaceuticals CEO and Dr. David Nutt to Discuss DMT Stroke Clinical Research Program Featured on BioPub Webcast Hosted by Dr. KSS MD, PhD
March 3, 2021 |  finance.yahoo.com
Algernon Pharmaceuticals to Conduct Phase 1 DMT Stroke Program Study with Hammersmith Medicines Research (UK)
March 1, 2021 |  finance.yahoo.com
Algernon Pharmaceuticals Appoints VP Research & Operations and Chief Medical Officer
March 1, 2021 |  finance.yahoo.com
Algernon Pharmaceuticals Provides Update on COVID-19 Phase 2b Final Study Data
February 17, 2021 |  finance.yahoo.com
BTV News Alert Video: Algernon Pharmaceuticals Inc. - Trial Complete for COVID-19 Treatment
February 11, 2021 |  finance.yahoo.com
Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol
February 10, 2021 |  finance.yahoo.com
Algernon CEO and CSO to Discuss New DMT Stroke Clinical Research Program Featured on BioPub Webcast Hosted by Dr. KSS MD, PhD
February 3, 2021 |  finance.yahoo.com
Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic Drug DMT "The Spirit Molecule"
February 2, 2021 |  benzinga.com
Proactive news headlines including Algernon Pharmaceuticals, Benchmark Metals, Imagine AR Inc and Q BioMed Inc
February 1, 2021 |  marketwatch.com
Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic Drug DMT “The Spirit Molecule”
February 1, 2021 |  finance.yahoo.com
Algernon Pharmaceuticals Receives Green Light from DSMB to Conduct Phase 3 Study of Ifenprodil for COVID-19
January 19, 2021 |  finance.yahoo.com
Algernon Pharmaceuticals Provides Reminder on Expiry Date of Accelerated Warrants
January 19, 2021 |  finance.yahoo.com
Algernon Highlights New Independent Research Review Identifying Ifenprodil as a Potential COVID-19 Treatment
January 11, 2021 |  finance.yahoo.com
Algernon Pharmaceuticals Announces Plans for 2021
January 7, 2021 |  finance.yahoo.com
Live Your 'PRICE IS RIGHT' Dreams With OLG's New $5 INSTANT PLINKO
January 4, 2021 |  finance.yahoo.com
Algernon Pharmaceuticals Provides Year End Summary of Key Activities
December 30, 2020 |  finance.yahoo.com
Algernon Pharmaceuticals Announces Acceleration of Expiry Date of Warrants
December 23, 2020 |  finance.yahoo.com
Algernon CEO and CSO to Discuss COVID-19 Study Interim Data Results Featured on Streetsmart Live! Webcast
December 21, 2020 |  finance.yahoo.com
Algernon Pharmaceuticals Provides Additional Information on Phase 2b/3 Ifenprodil COVID-19 Study Interim Data
December 17, 2020 |  finance.yahoo.com
Algernon CEO and CSO to Discuss COVID-19 Interim Data Results Featured on BioPub Webcast Hosted by Dr. KSS MD PhD
December 17, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:AGNPF
Previous Symbol
CUSIPN/A
CIKN/A
Webalgernonpharmaceuticals.com
Phone604 646 1553
EmployeesN/A
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable

MarketRank™

Overall MarketRank™

0.00 out of 5 stars

Medical Sector

1940th out of 1,969 stocks

Biotechnology Industry

119th out of 125 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$0.22
-0.03 (-12.02 %)
(As of 03/4/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AGNPF News and Ratings via Email

Sign-up to receive the latest news and ratings for AGNPF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Algernon Pharmaceuticals (OTCMKTS:AGNPF) Frequently Asked Questions

What stocks does MarketBeat like better than Algernon Pharmaceuticals?

Wall Street analysts have given Algernon Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Algernon Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are Algernon Pharmaceuticals' key executives?

Algernon Pharmaceuticals' management team includes the following people:
  • Mr. Christopher J. Moreau, CEO & Director (Age 56)
  • Mr. Michael S. M. Sadhra CA, CPA, CFO & Director (Age 52)
  • Mr. Mark Williams, Chief Science Officer

Who are some of Algernon Pharmaceuticals' key competitors?

Some companies that are related to Algernon Pharmaceuticals include (CHV) (CHV), (DDXS) (DDXS), (PREV) (PREV), (TNGN) (TNGN), 138267 (COM.TO) (COM), 17031 (MYM), Abattis Bioceuticals (ATTBF), Abzena plc (ABZA.L) (ABZA), Acrux (ACR), Actinogen Medical (ACW), AdAlta (1AD), ADiTx Therapeutics (ADTX), Admedus (AHZ), Almirall (LBTSF) and Amarantus BioScience (AMBS).
View all of AGNPF's competitors.

What is Algernon Pharmaceuticals' stock symbol?

Algernon Pharmaceuticals trades on the OTCMKTS under the ticker symbol "AGNPF."

How do I buy shares of Algernon Pharmaceuticals?

Shares of AGNPF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Algernon Pharmaceuticals' stock price today?

One share of AGNPF stock can currently be purchased for approximately $0.22.

What is Algernon Pharmaceuticals' official website?

The official website for Algernon Pharmaceuticals is algernonpharmaceuticals.com.

How can I contact Algernon Pharmaceuticals?

The company can be reached via phone at 604 646 1553.


This page was last updated on 3/5/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.